Bryan Czyzewski

Roche Covets Genentech for Good Reason

You do not seem to make a clear correlation between personalized medicine and Genentech. I would posit that DNA made its mark initially in the old vanguard of biotech, but by using its initial tenets, that of developing therapeutics through the understanding biology is what will drive it through the personalized medicine era. Sequencing may become routine enough to tell that you have a certain makeup that can predispose to disease or affect treatment regimens, but its what is done with that information that makes all the difference. Not one company really came out of the genomics era using any genomics information for the design of drugs.
If the founder of google now knows he may get parkinsons, well where do you think he might put his money?

Aegerion Pharmaceuticals: Capitalize on Cholesterol

Here's something I just noticed: if apoB levels are the new biomarker to follow for CHD risk assesment as the Farmington Study is leaning towards, then Isis' mipomersen and ezetimibe combo AEGR-733 both shoot it down 40 and 27 percent respectively. Now which would you rather take, an injection once a week as is necessary with Isis or a pill a day as in Aegerion's formulation.

Aegerion Pharmaceuticals: Capitalize on Cholesterol

Aegerion is trying to enter a very crowded market, true, but the combination market has some room, and this is where AEG-733 could really shine.